Clinical experience with cyclooxygenase-2 inhibitors

Area of Science:

• Pharmacology
• Gastroenterology
• Rheumatology

Background:

• Rheumatoid arthritis (RA) and osteoarthritis (OA) are chronic inflammatory conditions necessitating long-term pain management.
• Conventional non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for pain relief but are associated with significant gastrointestinal (GI) toxicities, including ulcerations and potentially fatal complications.
• There is a clinical need for pain management strategies that maintain therapeutic efficacy while minimizing gastric intolerance.

Purpose of the Study:

• To evaluate the efficacy and safety of selective cyclooxygenase-2 (COX-2) inhibitors compared to conventional NSAIDs for managing RA and OA.
• To assess whether selective COX-2 inhibitors offer a reduced risk of GI toxicity compared to traditional NSAIDs.
• To determine if selective COX-2 inhibitors could be considered as a first-line therapy for long-term pain relief in patients with RA and OA.

Main Methods:

• Comparative analysis of clinical trial data for selective COX-2 inhibitors (rofecoxib, celecoxib) and conventional NSAIDs in patients with RA and OA.
• Assessment of therapeutic efficacy based on established clinical endpoints for arthritis.
• Evaluation of GI safety profiles, including incidence of dyspepsia, ulcerations, and severe complications, comparing COX-2 inhibitors to NSAIDs and placebo.

Main Results:

• Selective COX-2 inhibitors demonstrated comparable efficacy to conventional NSAIDs in treating RA and OA symptoms.
• Patients receiving selective COX-2 inhibitors experienced significantly reduced GI toxicity compared to those on conventional NSAIDs.
• The incidence of gastric adverse effects with therapeutic doses of COX-2 inhibitors was often indistinguishable from placebo, highlighting their improved gastric safety profile.

Conclusions:

• Selective COX-2 inhibitors provide effective pain relief for RA and OA comparable to traditional NSAIDs.
• The significantly lower propensity for GI toxicity makes COX-2 inhibitors a safer alternative for long-term pain management.
• The safety and efficacy profile supports the consideration of selective COX-2 inhibitors as a first-line treatment option for patients requiring sustained pain relief from arthritis.